Near Infrared Spectroscopy (NIRS) as a Method for Measuring Oxidative Capacity of Skeletal Muscle Mitochondria in Breast Cancer and All Gynecological Cancer Patients
Part of paid clinical trials in Greenville, South Carolina.
- Sponsor
- University of South Carolina
- Study ID
- NCT06672497
- Status
- Recruiting
Conditions
- Breast Cancer
- Gynecologic Cancers
- Mitochondrial Function
Eligibility Criteria
- Sex
- FEMALE
- Age
- 20 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
Participants recruited for this study will be breast cancer or gynecological cancer patients who agree to participate in an exercise study examining the effects of chemotherapy on muscle mitochondrial oxidative capacity, a measure of skeletal muscle health. Participants will ride a stationary bicycle and the quadriceps muscle will be non-invasively evaluated.
Key Dates
- Start date
- Sep 7, 2021
- Status verified
- Nov 2024
- Primary completion
- Aug 31, 2025
- Completion
- Mar 31, 2026
Study Design
- Enrollment
- 30 participants (estimated)
Arms
- Arm: Patients diagnosed with breast or gynecological cancer and undergoing neoadjuvant chemotherapy.Females ages 20...
Primary Outcome Measure
Muscle mitochondrial oxidative capacity [ Time Frame: From enrollment to the end of chemotherapy treatment, an average of 12 weeks ]
Central Contacts
- Jennifer L Trilk, PhD864-455-1410
- Frankie Bennett, MS864-455-1410
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Prisma Health Cancer Institute | Greenville | South Carolina | 29605 | Jennifer L Trilk, PhD (PRINCIPAL_INVESTIGATOR) Randolph Hutchison, PhD (PRINCIPAL_INVESTIGATOR) Larry Gluck, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Greenville, SC
By condition
By specialty
By research site
Related Studies
- MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression ProfilesRecruiting · Agendia · Birmingham, Alabama
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerPHASE3 · Recruiting · Canadian Cancer Trials Group · Fairbanks, Alaska
- Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBCPHASE2 · Recruiting · Dana-Farber Cancer Institute · Stamford, Connecticut